Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
Authors
Keywords
Advanced prostate cancer, Hormone-sensitive prostate cancer, Castration-resistant prostate cancer, Prostate cancer treatment, Imaging, Genetics, Tumour genomic profiling, Next-generation sequencing, Lu-PSMA therapy, PARP inhibition
Journal
EUROPEAN UROLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-04-18
DOI
10.1016/j.eururo.2022.04.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
- (2021) Vedang Murthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Mary B. Daly et al. Journal of the National Comprehensive Cancer Network
- Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
- (2021) Tamara L. Lotan et al. MODERN PATHOLOGY
- UpFrontPSMA: A Randomised Phase 2 Study of Sequential 177 Lu‐PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone‐Naïve Prostate Cancer
- (2021) Nattakorn Dhiantravan et al. BJU INTERNATIONAL
- E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
- (2021) Francesco Ceci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer
- (2021) Simona Malaspina et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.
- (2021) Nobuaki Matsubara et al. JOURNAL OF CLINICAL ONCOLOGY
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- Radiotherapy of oligometastatic prostate cancer: a systematic review
- (2021) Paul Rogowski et al. Radiation Oncology
- Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer
- (2021) Adnan Ali et al. JAMA Oncology
- Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer
- (2021) Rebeca Lozano et al. EUROPEAN JOURNAL OF CANCER
- Metastatic Prostate Cancer: In Search of More Granularity
- (2021) Alok K. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
- (2021) G. Attard et al. ANNALS OF ONCOLOGY
- LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
- (2021) K. Fizazi et al. ANNALS OF ONCOLOGY
- Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis
- (2021) Hongyan Cheng et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901)
- (2021) Louise Emmett et al. BJU INTERNATIONAL
- Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
- (2021) Renato D. Lopes et al. CIRCULATION
- Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer
- (2021) David A. Pattison et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
- (2021) Johann S de Bono et al. LANCET ONCOLOGY
- Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
- (2021) Andrei Gafita et al. LANCET ONCOLOGY
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
- (2021) Daniel Groener et al. EJNMMI Research
- Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection
- (2021) Thomas A. Hope et al. JAMA Oncology
- The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
- (2021) N.Y.L. Ngoi et al. ESMO Open
- Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer
- (2021) Yawei Li et al. iScience
- Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
- (2021) Ursula M. Vogl et al. EUROPEAN JOURNAL OF CANCER
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations
- (2020) Zsofia Sztupinszki et al. CLINICAL CANCER RESEARCH
- New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide
- (2020) Florian Rosar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
- (2020) Silke Gillessen et al. EUROPEAN UROLOGY
- Knowing what’s growing: Why ductal and intraductal prostate cancer matter
- (2020) Mitchell G. Lawrence et al. Science Translational Medicine
- PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review
- (2020) Lars J. Petersen et al. CANCER IMAGING
- Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
- (2020) Michael S Hofman et al. LANCET
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
- (2020) Neal D. Shore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
- (2020) Ryan Phillips et al. JAMA Oncology
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) C. Parker et al. ANNALS OF ONCOLOGY
- Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study
- (2020) Andrei Gafita et al. EUROPEAN UROLOGY
- When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities
- (2020) Nora Sundahl et al. EUROPEAN UROLOGY
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
- (2020) Philip Cornford et al. EUROPEAN UROLOGY
- Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
- (2020) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
- (2020) Wassim Abida et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
- (2020) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer
- (2020) Stephen E. Lincoln et al. JAMA Network Open
- Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference
- (2020) Kendal Jensen et al. JAMA Oncology
- Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
- (2020) Antje Neeb et al. EUROPEAN UROLOGY
- Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team
- (2019) Declan G Murphy et al. BJU INTERNATIONAL
- Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
- (2019) Gonçalo Ferreira et al. CANCER IMAGING
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Matched-pair comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy
- (2019) Isabel Rauscher et al. JOURNAL OF NUCLEAR MEDICINE
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
- (2019) Alex P. Hoyle et al. EUROPEAN UROLOGY
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
- (2019) N W Clarke et al. ANNALS OF ONCOLOGY
- TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
- (2019) Michael S. Hofman et al. BJU INTERNATIONAL
- Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
- (2019) John Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations
- (2018) René Böttcher et al. BMC CANCER
- Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
- (2018) Shankar Siva et al. EUROPEAN UROLOGY
- Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
- (2018) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
- (2018) Silke Gillessen et al. EUROPEAN UROLOGY
- Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
- (2018) Veda N. Giri et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- (2018) Christos E. Kyriakopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
- (2018) Piet Ost et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
- (2018) Liselotte M.S. Boevé et al. EUROPEAN UROLOGY
- Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
- (2018) Anna Yordanova et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Early experience of rechallenge 177Lu-PSMA radioligand therapy after an initial good response in patients with mCRPC
- (2018) Andrei Gafita et al. JOURNAL OF NUCLEAR MEDICINE
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
- (2018) Christopher C Parker et al. LANCET
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum sensitivity in metastatic prostate cancer: does histology matter?
- (2017) Michael S. Humeniuk et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
- (2016) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
- (2015) S. Gillessen et al. ANNALS OF ONCOLOGY
- Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis
- (2015) Gail P. Risbridger et al. EUROPEAN UROLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
- (2013) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer
- (2010) Matthew R. Smith et al. JOURNAL OF UROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More